Medical Marijuana Inc. Advisory Committee and Board of Directors Update
SAN DIEGO, June 18, 2012 /PRNewswire/ — Medical Marijuana Inc. (OTC.PK: MJNA) a leading cannabis and hemp industry innovator, is pleased to announce the appointment of the CanCHEW Bio-technologies executive team Dr. George Anastassov, Dr. Philip A. Van Damme and Lekhram Changoer to its Board of Directors and Medical Advisory Committee.
Dr. George E. Anastassov, Director
George E. Anastassov, MD, DDS, graduated with BA Degree, Fine Arts School, Sofia, Bulgaria in 1981, followed by MD Degree, Medical Academy, Higher Medical Institute Sofia, Bulgaria, and a DDS Degree, New York University College of Dentistry, New York, New York In 1990.
Between 1988 and 1991 held Clinical Extern positions at the, Department of Oral and Maxillofacial Surgery, Bellevue Hospital Centre, New York. Clinical Assistant, Department of Plastic and Reconstructive Surgery and Microsurgery, Memorial Sloan-Kettering Cancer Centre, New York, and Clinical Extern, at the Department of Oral and Maxillofacial Surgery, Bellevue Hospital Centre, New York.
Operating in private practice between 1990 – 1993 and with a longer term private practice role between 1991 – 1999 at East Village Dental Group. New York, N.Y. Dr Anastassov additionally executed various post doctoral education positions notably; A Fellowship in Cranio-Maxillofacial Surgery. (Professor H.P.M. Freihofer), The Catholic University, St. Radboud Hospital, Nijmegen, the Netherlands 1994. Chief Resident, Department of Oral and Maxillofacial Surgery, Montefiore Medical Centre, Albert Einstein College of Medicine, Bronx, New York between June 1995 and June 1996. Followed by a further Fellowship in Craniofacial and Base of Skull Surgery, at the department of Cranio-Maxillofacial and Plastic and Reconstructive Surgery, Wilhelms University, Munster, Germany between June 1996 and June 1997.
Eventually returning to a variety of Hospital appointments in the US between 1997 – 2007: including Associate Director, Department of Maxillofacial Surgery, Elmhurst Hospital Centre, Queens, N.Y. Assistant-Attending, Department of Dentistry, The Mount Sinai Hospital. New York. Consultant in Maxillofacial Surgery, Bronx VA Hospital Centre, Bronx, N.Y. 1997 – present, and three additional ongoing roles, Attending, Department of Maxillofacial Surgery, Elmhurst Hospital Centre, Queens, N.Y. Attending, Department of Dentistry, the Mount Sinai Hospital. New York, N.Y. Attending Surgeon, Department of Otolaryngology/ Head and Neck Surgery, Beth Israel Medical Centre, New York. Visiting Professor, Department of Crania-Maxillofacial Surgery and Plastic and Reconstructive Surgery, Wilhelm’s University, Munster, Germany. Associate Clinical Professor of Oral and Maxillofacial Surgery. The Mount Sinai School of Medicine.
Editorially, Dr. Anastassov is presently active as Editorial Consultant – ‘The Journal of Oral Surgery, Oral Medicine, Oral Pathology and Radiology’. Editorial Board Member – ‘International Journal of Oral and Maxillofacial Surgery’ Since 2000. And also Editorial Board Member – ‘Folia Medica’ and Editorial Consultant – ‘Head and Face Medicine’.
Dr. Anastassov was granted Fellowship to the American College of Oral and Maxillofacial Surgeons in 2000 and Fellowship to the American College of Dentistry in 2005, and with Chairman appointments during the First International Congress of the Cleft Lip and Palate Foundation “Cleft 2000″, Chairman, Facial Aesthetics Section. XV Congress of the European Association for Cranio-Maxillofacial Surgery. Edinburgh, UK, September 5-9, 2000 and Chairman, Aesthetic Surgery. XVI Confidential Executive Summary_Sanammad_25102010 14 Congress of the European Association for Cranio-Maxillofacial Surgery. Munster, Germany, September 3-7, 2002.
Dr. Anastassov holds 9 US & European Professional Society Membership: including a certified member of American Board of Oral and Maxillofacial Surgery, additionally with 43 journal publications and 75 international guest lecture’s to his credit.
Dr. Philip A. Van Damme, Director
Dr. Philip. A. Van Damme, DMD MD PhD, studied dentistry at the Utrecht University Dental School (Rijksuniversiteit Utrecht, The Netherlands) from 1971 till February 1977, and fulfilled his military duty in the Dutch Royal Navy (Koninklijke Marine), from May 1977 till October 1978, as Lieutenant-Dentist (LtZTa2OC), partly on board of the supply ship HMS Poolster.
Ongoing, he studied medicine at the Utrecht University Medical School (Rijksuniversiteit Utrecht) till January 1983. Training in general surgery in the Joannes de Deo Stichting Hospital Utrecht (Ziekenhuis Overvecht) followed from July 1983 till April 1984, meanwhile taking the International ECFMG/VQE examinations in Paris, France.
He was trained in Oral & Maxillofacial Surgery in the University Hospital Nijmegen (AZN St Radboud, Katholieke Universiteit Nijmegen, The Netherlands) from May 1984 till May 1988 (Chair: Prof. Dr. H.P.M. Freihofer). He followed various rotations and courses abroad and became a full-time staff member, consultant, university teacher, with apart from patient care tasks, teaching, training and research activities.
He defended his PhD Thesis entitled: Subperiosteal Palatal Soft Tissue Expansion: An experimental study in growing domestic cats, on December 06 1996 at the Nijmegen University (Katholieke Universiteit Nijmegen).
Ever since he was Research Coordinator at the Department Oral & Maxillofacial Surgery in the University Hospital Nijmegen Medical Centre, Coordinator (Facial)Traumatology, member of different taskforces (e.g. Pain-Classification, Temporo-Mandibular-Dysfunction) till December 2007, and took part in the Dutch Noma Foundation (Nederlandse Noma Stichting) team missions to Nigeria and Mali.
He was teacher/trainer in various courses, e.g. Traumatology, Advanced AO-course, Course Around the Nose, and he took courses in Integral Medical Management (Radboud University Nijmegen 2005-2006).
Since August 2005, he is part-time staff member-consultant in the Maas Hospital Boxmeer / Beugen (Maasziekenhuis Pantein) and Guest Consultant in the Canisius-Wilhelmina Ziekenhuis (CWZ ) in Nijmegen, Kliniek Klein Rosendael (MediNova private clinic) in Rozendaal, ViaSana (private clinic) in Mill, and free lance replacing consultant in different places in The Netherlands.
Since July 2009, he is full-time staff member-consultant in the Rivas Beatrix Hospital Gorinchem / Lingepoliclinics Leerdam, The Netherlands, in close cooperation with Dr. Peter A. Blijdorp DMD MD PhD.
He was Visiting Professor in the Mount Sinai Hospital in New York, USA, and Visiting Surgeon in the Burdenko Institute in Moscow, Russia, both in 2004.
Since 1999 he is Section Editor of the Journal of Cranio-Maxillo Facial Surgery, for the sections Research, Development and New Horizons, and Reviewer for different other scientific journals. There are more than 70 PubMed listed publications and he presented more than 100 times at national and international scientific meetings.
Together with Prof. George E. Anastassov MD DDS FAC, he has a patent application (US20110097283 – EP2280687 – CA2719830) on chewing gum compositions comprising cannabinoids.
After December 2007, he is Director-owner of Mareda Holding BV(investment company) and President-founder of Stichting Sanammad (intellectual property foundation together with Lekhram Changoer MSc BSc).
Lekhram Changoer, Director
Lekhram Changoer has a Bachelor Degree in Analytical/Organic chemistry and Masters Degree in Organic Chemistry. He has over 20 years of experience in the area of Sales & Marketing, R&D, product development, and quality assurance of technical, consumer healthcare and pharmaceutical products.
In 1992 he started his career; he joined IWC Chemical products BV where he was responsible for the development of functional coatings and corrosion inhibitors for the chemical industry like i.e. Yara, Kemira, and others. Hereafter he joined Scott Specialty Gases BV where he was responsible for managing the R&D, QC and QA of functional calibration gases for the petrochemical and automotive Industry for companies like i.e. Mercedes Benz, Rolls Royce, Dera, Shell, Exxon, and General Electric.
In the area of consumer healthcare products, he worked on the development of cosmetics and medical device products for various retail chains and consumer healthcare companies. At Codi International BV he was responsible for managing product development in the field of wet wipes and successfully developed products for companies like i.e. Proctor & Gamble, Sara Lee, Henkel and Reckitt Benckiser. In 1999 he continued his career at Royal Sanders BV in the position of R&D & QC manager and was responsible for the development of cosmetics, medical devices and other healthcare products for clients like i.e. Sara Lee, Colgate Palmolive, Virgin Cosmetics, Keune Cosmetics and private labels for i.e. Ahold, AC Watson, DM and Rossmann retail chains.
In 2002 he joined the Ardoz/NGen group of companies in the position of Managing Director. During this period he achieved in filing new patents in the field of active oxygen therapy including the accreditation of the products by the Dutch Skin Foundation and the British Dental Health Foundation. He developed new oral healthcare drug applications for periodontitis, peri-implantitis/bone repair and oral mucositis. The OTC products with active oxygen incl. new chewing gum application (for Perfetti van Melle in Italy) were successfully launched under his lead in markets at i.e. Boots, Ahold and El Corte Ingles Pharmacy retail and pharmacy chains under the cosmetic 76/768/EEC and medical device 93/42/EEC directive.
In 2010 he co-founded APeT BV which focuses on a first of its kind patented therapy for psychiatric diseases like ADHD and Autism as a replacement for methylphenidate and analogs. This therapy involves an in-house developed diagnose and treatment with a body own compound. The impact on national healthcare is so important that he has been able to get the largest Dutch insurance company to fund the clinical trial, after which it will most probably become the new standard of care. A new patented pharmacotherapy was filed, which will guarantee protection of the therapy as well as patient therapy loyalty.
Together with Prof. George E. Anastassov MD DDS FAC and Dr. Philip. A. Van Damme, DMD MD PhD Sanammad foundation (www.sanammad.com ) was established in 2008 which holds patented technology on chewing gum compositions comprising cannabinoids.
He is also co-founder of CFM Pharma BV(www.cfmpharma.com ) which holds patented technologies and focuses on the prevention of secondary injury in indications like: deep burn wounds, myocardial infarct, general trauma and GCP Dental BV (www.gcp-dental.com) which has developed a 100% patented biocompatible material for restorative dental applications (which Glass Carbomer® Technology allows the tooth to heal itself) with global market approach.
“We are very pleased with the closing of our Canchew biotechnologies company and we are honored to have George, Philip and Lekhram appointed to our board, we are looking forward to updating our shareholders and the market on the development of the Canchew products and clinical development,” said Michael Llamas, President of Medical Marijuana Inc.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally friendly, economically sustainable businesses, while increasing shareholder value.
Medical Marijuana Inc. does not grow, sell or distribute any substances that violate United States Law or the controlled substance act.
For more information, please visit the company’s website at: www.MedicalMarijuanaInc.com
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
Investor Relations Contact:
Stuart T. Smith
SOURCE Medical Marijuana, Inc.